Abstract-Evidence supports early intensive blood pressure (BP) lowering in acute intracerebral hemorrhage, but uncertainty persists over whether potential benefits and harms vary according to the magnitude of BP reduction. We aimed to determine whether larger systolic BP (SBP) reductions were associated with better outcomes in participants of the Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT2). INTERACT2 was an international, open, blinded end point, randomized controlled trial of patients with spontaneous intracerebral hemorrhage (<6 hours) and elevated SBP (150-220 mm Hg) assigned to intensive (target SBP <140 mm Hg) or guideline-recommended (SBP <180 mm Hg) treatment. Associations of BP reduction (baseline minus average of achieved SBP) during 3 time periods post randomization (15-60 minutes, 1-24 hours, and 2-7 days) on poor outcome (death or major disability) at 90 days were analyzed in multivariable logistic regression models with odds ratios and 95% confidence intervals. Larger SBP reductions within the first hour after randomization were associated with lower risks of poor outcome: compared with minimal reduction (<10 mm Hg), odds ratios were 0.80 (95% confidence interval, 0.63-1.02) for moderate (10-20 mm Hg) and 0.65 (0.52-0.82) for large (≥20 mm Hg) reductions (P trend <0.01). Similar associations were also observed for SBP reductions during 1 to 24 hours (P<0.01) and 2 to 7 days (P 0.02). No heterogeneity in associations for patients above or below baseline SBP 180 mm Hg was reported (P>0.30). Optimal recovery from intracerebral hemorrhage was observed in hypertensive patients who achieved the greatest SBP reductions (≥20 mm Hg) in the first hour and maintained for 7 days. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00716079.
H igh blood pressure (BP) is common in patients with spontaneous intracerebral hemorrhage (ICH) 1, 2 and predicts a poor outcome, [3] [4] [5] [6] [7] but data have been conflicting on the effects of BP lowering treatment. Some studies have implied adverse effects from reducing systolic BP (SBP), [8] [9] [10] whereas others have indicated clinical improvement with higher SBP reduction [11] [12] [13] [14] or no benefits at all of such treatment in ICH. 15 An important meta-regression analysis of randomized controlled trials of altered BP in acute stroke showed a J-shaped relationship, with the best outcomes from modest SBP reduction (<10 mm Hg), but the number of patients included with ICH was limited. 16 There has been the longstanding clinical concern that early intensive BP lowering may induce significant ischemic injury to the brain or other vascular beds in this patient group. However, the recently completed, main phase Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT2) showed improved functional recovery without any harm from a more intensive strategy of BP lowering (target SBP, <140 mm Hg within 1 hour using intravenous agents) than contemporary guideline-recommended BP control (SBP, <180 mm Hg) in patients with ICH of mild to moderate severity and hypertension (SBP, 150-220 mm Hg). 17 Moreover, several smaller studies including the Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure (ICH-ADAPT) trial, 18 and observational studies in the first Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) study 14 and the Stroke Acute Management With Urgent Risk-Factor Assessment and Improvement-Intracerebral Hemorrhage Study (SAMURAI-ICH Study), 19 have also demonstrated safety of intensive BP lowering in ICH. Despite this progress, there remains some uncertainty on the balance of safety and efficacy from larger reductions in SBP in ICH. The aim of this analysis of the INTERACT2 data set was to determine variation in the treatment effects with different degrees of SBP lowering during the first 7 days after ICH onset on the risk of poor outcomes at 90 days, and in particular to assess whether benefit:harm varied according to the level of BP at presentation.
Methods
The INTERACT2 has been described in detail elsewhere. 17, 20, 21 In brief, the study included 2829 adult patients with computed tomography-confirmed acute ICH within 6 hours of onset with sustained elevated SBP level (150-220 mm Hg) who were able to receive active management. Exclusion criteria included (1) a clear indication for, or contraindication to, intensive BP lowering; (2) severe neurological symptoms, concurrent medical condition, high likelihood of death within 24 hours, or massive ICH; and (3) early planned surgical intervention. The study protocol was approved by the ethics committee at each participating site and the procedures followed were in accordance with institutional guidelines. Written informed consent was obtained from each patient or their legal surrogate.
Patients were randomly assigned to receive early intensive BP lowering treatment (according to a standardized protocol to achieve a SBP goal of <140 mm Hg within 1 hour, commencing with intravenous and changed when feasible to oral agents, to maintain this level for at least 7 days) or guideline-recommended best practice BP control (SBP <180 mm Hg). BP levels were recorded in the nonparetic arm with the patient supine using either an automated device or a manual sphygmomanometer with an appropriate size cuff; the use of which was standardized for participants at each site. Baseline BP was measured twice with an interval of ≥2 minutes and the mean of these 2 measurements was used. BP was recorded every 15 minutes for the first hour, then 6 hourly until 24 hours, and twice in the morning and evening from days 2 to 7 (or until discharge). Mean SBP levels were significantly different between randomized groups from 15 minutes to day 7 post randomization; 150 mm Hg in the intensive group (462 [33%] achieved the target SBP) compared with 164 mm Hg in the guideline group (difference, 14 mm Hg; P<0.001) at 1 hour. Mean (SD)-achieved SBPs in the 1-to 24-hour and 2-to 7-day periods were 142 (13) mm Hg and 155 (14) mm Hg and 140 (11) mm Hg and 149 (13) mm Hg, in the intensive and guideline groups, respectively. 21 The primary outcome was death or major disability defined by the modified Rankin Scale (mRS), 22 and the secondary outcome was physical function across all 7 levels in an ordinal shift analysis of the mRS, 23 at 90 days post randomization. SBP reduction was defined as baseline SBP minus the mean of achieved SBP levels during 3 periods post randomization (15- Patients were further stratified by baseline SBP into 2 groups: <180 and ≥180 mm Hg. A logistic regression model was used to investigate the effects of SBP reduction on the outcomes in these 2 groups as SBP reduction increased per 1 SD: these were 18.3, 19.0, and 18.3, for 15 to 60 minutes, 1 to 24 hours, and 2 to 7 days, respectively. The effects were compared between the 2 groups by adding an interaction term to the adjusted statistical model. This analysis was repeated with patients further stratified by randomized treatment. Data are reported with odds ratios and 95% confidence intervals. A 2-sided P value <0.05 was set as the level for statistical significance. All statistical analyses were performed using SAS version 9.3 (SAS institute, Cary, NC).
Results
After excluding patients with missing information on the primary outcome and of ∆SBP values, there were 2776 included in analysis of ∆SBP 15-60M , 2781 for ∆SBP 1-24H , and 2704 for ∆SBP 2-7D ( Figure S1 in the online-only Data Supplement). Table 1 shows baseline characteristics stratified by ∆SBP 15-60M . Patients with different degrees of SBP reduction (<10, 10-20, and ≥20 mm Hg) had broadly similar characteristics, except that those with the lowest reduction were more often men, recruited from China, had greater proportion with intraventricular hemorrhage, and were less likely to have been allocated to the intensive BP lowering group. Similar differences in baseline characteristics were found in the ∆SBP 1-24H and ∆SBP 2-7D groups (Tables S1 and S2 ). Figure S2 shows individual ∆SBP at the 3 time points. Median values (mm Hg) of ∆SBP 15-60M were 1.8, 15.0, and 30.8, for the <10, 10 to 20, and ≥20 mm Hg groups, respectively; values for ∆SBP 1-24H were 2.6, 15.5, and 36.8 and ∆SBP 2-7D were 3.6, 15.8, and 38.1. Only 1% of patients who achieved moderate or larger reductions in the first hour were unable to maintain SBP levels subsequently (Table S3) . Achieved BP at each follow-up time point is are outlined elsewhere. 17, 21, 24 The number of participants who were either dead or had major disability (mRS, 3-5) at 90 days was 1504 (53.8%; 336 [12. 0%] dead, 1168 [41.8%] major disability). The distribution of the mRS scores in each group for each period is shown in Figure S3 .
Larger reductions in ∆SBP 15-60M were associated with lower risks of death or major disability: compared with patients with SBP reduction of <10 mm Hg, odds ratio 0.80 (95% confidence interval, 0.63-1.02) for patients with 10 to 20 mm Hg SBP reduction and 0.65 (95% confidence interval, 0.52-0.82) for those with ≥20 mm Hg (P trend <0.01; Figure 1 ). Similar associations were also observed for ∆SBP 1-24H (P trend <0.01) and ∆SBP 2-7D (P trend=0.02). The trend of greater risk reductions with greater SBP reduction was confirmed by analyses using thirds of SBP reduction (all P trend <0.01; Figure S4 ) and analyses using SBP reduction as a continuous variable (Table 2) . Similar results were observed for the (shift) distribution of mRS scores (all P trend <0.01; Figure 1 ) and death (all P trend <0.01; Figure 2 ).
There was no significant difference in associations between SBP reduction and poor outcome between patients with baseline SBP levels above or below 180 mm Hg for any of the 3 time periods (P homogeneity > 0.3 for all; Table 2 ). Similarly, no associations were observed in patients who received intensive and guideline-recommended treatments, respectively (P homogeneity > 0.1 for all; Table S4 ).
Discussion
In these post hoc analyses of INTERACT2, we have shown that larger SBP reductions in the acute phase of ICH are associated with lower risks of a poor outcome, defined by the combination of either death or major disability. This relationship is consistent for BP reduction in the hyperacute and acute phases of ICH, and whether the baseline SBP is above or below the conventional SBP target 180 mm Hg. These data reinforce potential beneficial effects of rapid lowering of elevated SBP within the first few hours after presentation, but also for consistent and sustained control of SBP over the subsequent week in ICH, irrespective of SBP level at presentation.
The few previous studies that have investigated the degree of early BP reduction and clinical outcomes in acute ICH have produced conflicting results. 5, 10, 12, 13, 15 For example, a prospective study of 105 patients with ICH showed that a rapid decline in mean BP within 24 hours was associated with higher inhospital mortality, 10 whereas another study involving 688 patients with ICH showed no association between early SBP reduction and death or disability at 3 weeks. 15 A prospective study of 122 patients with ICH demonstrated lower rates of early neurological deterioration after ICH to be associated with larger SBP reductions, even with ≥64 mm Hg. 12 Such variability likely relates to differences in study design, patient selection, sample size, and measurement error, in particular of SBP levels according to time from ICH onset.
More recent prospective studies with standardized and controlled evaluations of different intensities of SBP lowering in ICH have shown better outcomes related to greater SBP reduction. In particular, the ATACH I study found a lower frequency of poor outcome at 3 months in patients with larger SBP reduction at 2 hours.
14 Moreover, an epidemiological study comparing premorbid with immediate postmorbid BP suggests that SBP is substantially raised compared with usual premorbid levels after ICH, whereas acute-phase SBP after major ischemic stroke is much closer to the accustomed long-term premorbid levels. 25 This reinforces suggestions that early lowering of SBP may not be associated with potential adverse consequences that have been reported in acute ischemic stroke. 16 An important mechanism underlying potential beneficial effects of BP reduction in ICH is reduction in hydrostatic pressure within the hemorrhage with subsequent attenuation of its expansion. 26, 27 Other mechanisms involve reduction in rebleeding, perihematomal edema, and early stroke recurrence. [28] [29] [30] [31] Our results suggest both early (ie, hematoma growth) and later (perihematomal edema) mechanisms of effect of elevated SBP in ICH.
A key strength of this study was the large sample size that provides reassurance over precision and reliability around the estimates of association. Another is the wide range of patients who were included from a variety of hospitals in many countries, which along with the use of a range of BP lowering regimes enhances the generalizability of these results. Aside from SBP, we were unable to demonstrate major confounding because of differences in the characteristics of patients between groups, and there was consistency in the results through 3 sets of analyses. Finally, we overcome the wide time window (≤24 or 28 hours post-ICH onset) of patient recruitment in previous studies by restricting inclusion to patients within 6 hours after ICH onset for the testing of rapid BP lowering.
However, our study is limited by selection bias related to a clinical trial population where patients with severe ICH or early planned surgery were excluded. Furthermore, the heterogeneity of treatments used in the trial creates uncertainty on the most desirable agent and BP lowering dosing protocol, whereas the imprecise and low frequency of BP measurements, and post hoc observation nature of these analyses, raise the potential for random error and residual confounding from imbalances between groups.
Perspectives
Optimal protection against death or major disability after ICH was observed in patients without severe ICH and early planned surgery who achieved the greatest SBP reductions, ≤30 mm Hg in the first hour after randomization and maintained consistently for 7 days.
Sources of Funding
The What Is New?
• Accumulating evidence supports the use of early intensive blood pressure (BP) lowering in acute intracerebral hemorrhage, but uncertainty persists over whether potential benefits and harms vary according to the magnitude of BP reduction. We aimed to determine whether larger systolic BP reductions were associated with better outcomes in participants of a large clinical trial, Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT2).
What Is Relevant?
• Optimal recovery from intracerebral hemorrhage was observed in hypertensive patients who achieved the greatest systolic BP reductions (≥20 mm Hg) in the first hour and maintained for 7 days.
Summary
In these post hoc analyses of the INTERACT2 study, we showed that optimal protection against death or major disability after acute intracerebral hemorrhage was observed in patients who achieved the greatest systolic BP reductions, ≤30 mm Hg in the first hour after initiation of treatment and maintained consistently for 7 days. Table S1 . Baseline characteristics of patients, according to degree of blood pressure reduction from baseline to average achieved blood pressure between 1 and 24 hours, postrandomization Table S2 . Baseline characteristics of patients, according to degree of blood pressure reduction from baseline to average achieved blood pressure over days 2 to 7, postrandomization Table S3 . Outcomes according to BP reductions levels Table S4 . Relationship between degree of blood pressure reductions and clinical outcomes stratified by randomized intensive BP lowering treatment at different time points Figure S1 . Study profile Figure S2 . Individual changes in blood pressure at the 3 timepoints Figure S3 . Distribution of scores on the modified Rankin scale (mRS) by systolic blood pressure (SBP) reduction degree at different time points Figure S4 . Risk of death or major disability according to blood pressure reduction levels (thirds) during the follow-up period 3   Table S1 . Baseline characteristics of patients, according to degree of blood pressure reduction from baseline to average achieved blood pressure between 1 and 24 hours, post-randomization 
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